In vitro evaluation of antisense RNA efficacy against filovirus infection, by use of reverse genetics

Journal of Infectious Diseases

Volumn 196, Issue SUPPL. 2, 2007, Pages

  Groseth, Allison ^a,b   Hoenen, Thomas ^a,c   Alimonti, Judie B ^a   Zielecki, Florian ^a,c,d   Ebihara, Hideki ^a,e,f   Theriault, Steven ^a   Ströher, Ute ^a,b   Becker, Stephan ^c,d   Feldmann, Heinz ^a,b,g  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

^d ROBERT KOCH INSTITUTE   (Germany)

^e JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^f UNIVERSITY OF TOKYO   (Japan)

^g NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GREEN FLUORESCENT PROTEIN; NUCLEOPROTEIN; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; COMPLEMENTARY RNA; VIRUS RNA;

ANIMAL CELL; ANTIVIRAL ACTIVITY; BIOSAFETY; CELL CULTURE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG TARGETING; EBOLA VIRUS; ELECTROPORATION; FILOVIRUS; FLOW CYTOMETRY; GENOME ANALYSIS; GUINEA PIG; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS INFECTION; ANIMAL; ARTICLE; CELL LINE; CERCOPITHECUS; FILOVIRIDAE; GENE THERAPY; GENETICS; HAPLORHINI; KIDNEY; METHODOLOGY; PATHOGENICITY; VERO CELL; VIRUS GENOME;

ANIMALS; CELL LINE; CERCOPITHECUS AETHIOPS; FILOVIRIDAE; FILOVIRIDAE INFECTIONS; GENE THERAPY; GENOME, VIRAL; HAPLORHINI; HUMANS; KIDNEY; RNA, ANTISENSE; RNA, SMALL INTERFERING; RNA, VIRAL; VERO CELLS;

EID: 38449111730     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/520604     Document Type: Conference Paper

References (32)

1. Peters CJ, Khan A. Filovirus diseases. Curr Top Microbiol Immunol 1999; 235:85-95.
2. Geisbert T, Hensley L. Ebola virus: new insights into disease aetiopathology and possible therapeutic interventions. Expert Rev Mol Med 2004; 6:1-24.
3. Haasnoot J, Berkhout B. RNA interference: its use as antiviral therapy. Handb Exp Pharmacol 2006; 173:117-50.
4. Fabani M, Turner J, Gait M. Oligonucleotide analogs as antiviral agents. Curr Opin Mol Ther 2006; 8:108-14.
5. Fowler T, Bamberg S, Möller P, et al. Inhibition of Marburg virus protein expression and viral release by RNA interference. J Gen Virol 2005; 86:1181-8.
6. Bamberg S, Kolesnikova L, Möller P, Klenk H-D, Becker S. VP24 of Marburg virus influences formation of infectious particles. J Virol 2005; 79:13421-33.
7. Enterlein S, Warfield K, Swenson D, et al. VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice. Antimicrob Agents Chemother 2006; 50:984-93.
8. Geisbert T, Hensley L, Kagan E, et al. Postexposure protection of guinea pigs against a lethal Ebola virus challenge is conferred by RNA interference. J Infect Dis 2006; 193:1650-7.
9. Warfield KL, Swenson DL, Olinger GG, et al. Gene-specific counter-measures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers. PLoS Pathog 2006; 2:e1.
10. Khvorova A, Reynolds A, Jayasena S. Functional siRNAs and miRNAs exhibit strand bias. Cell 2003; 115:209-16.
11. Schwarz D, Hutvágner G, Du T, Xu Z, Aronin N, Zamore P. Asymmetry in the assembly of the RNAi enzyme complex. Cell 2003; 115:199-208.
12. Reynolds A, Leake D, Boese Q, Scaringe S, Marshall W, Khvorova A. Rational siRNA design for RNA interference. Nat Biotechnol 2004; 22:326-30.
13. Yuan B, Latek R, Hossbach M, Tuschl T, Lewitter F. siRNA Selection Server: an automated siRNA oligonucleotide prediction server. Nucleic Acids Res 2004; 32:W130-4.
14. Henschel A, Buchholz F, Habermann B. DEQOR: a Web-based tool for the design and quality control of siRNAs. Nucleic Acids Res 2004;32:W113-20.
15. Klee E, Shim K, Pickart M, Ekker S, Ellis L. AMOD: a morpholino oligonucleotide selection tool. Nucleic Acids Res 2005; 33:W506-11.
16. Mühlberger E, Lötfering B, Klenk H-D, Becker S. Three of the four nucleocapsid proteins of Marburg virus, NP, VP35, and L, are sufficient to mediate replication and transcription of Marburg virus-specific monocistronic minigenomes. J Virol 1998; 72:8756-64.
17. Mühlberger E, Weik M, Volchkov V, Klenk H-D, Becker S. Comparison of the transcription and replication strategies of Marburg virus and Ebola virus by using artificial replication systems. J Virol 1999; 73:2333-42.
18. Modrof J, Mühlberger E, Klenk H-D, Becker S. Phosphorylation of VP30 impairs Ebola virus transcription. J Biol Chem 2002; 277:33099-104.
19. Weik M, Modrof J, Klenk H-D, Becker S, Mühlberger E. Ebola virus VP30-mediated transcription is regulated by RNA secondary structure formation. J Virol 2002; 76:8532-9.
20. DuBridge R, Tang P, Hsia H, Leong P, Miller J, Calos M. Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. Mol Cell Biol 1987; 7:379-87.
21. Hoenen T, Groseth A, Kolesnikova L, et al. Infection of naive target cells with virus-like particles: implications for the function of Ebola virus VP24. J Virol 2006; 80:7260-4.
22. Ebihara H, Theriault S, Neumann G, et al. In vitro and in vivo characterization of recombinant Ebola viruses expressing enhanced green fluorescent protein. J Infect Dis 2007; 196(Suppl 2):S313-22 (in this supplement).
23. Becker S, Klenk H-D, Mühlberger E. Intracellular transport and processing of the Marburg virus surface protein in vertebrate and insect cells. Virology 1996; 225:145-55.
24. Brown K, Chu C, Rana T. Target accessibility dictates the potency of human RISC. Nat Struct Mol Biol 2005; 12:469-70.
25. Overhoff M, Alken M, Far R, et al. Local RNA target structure influences siRNA efficacy: a systematic global analysis. J Mol Biol 2005; 348:871-81.
26. Basler C, Wang X, Mühlberger E, et al. The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc Natl Acad Sci USA 2000; 97:12289-94.
27. Reid S, Leung L, Hartman A, et al. Ebola virus VP24 binds karyopherin a1 and blocks STAT1 nuclear accumulation. J Virol 2006; 80:5156-67.
28. Kash J, Mühlberger E, Carter V, et al. Global suppression of the host antiviral response by Ebola- and Marburgviruses: increased antagonism of the type I interferon response is associated with enhanced virulence. J Virol 2006; 80:3009-20.
29. Bennasser Y, Le S, Benkirane M, Jeang K. Evidence that HIV-1 encodes an siRNA and a suppressor of RNA silencing. Immunity 2005; 22:607-19.
30. Li W, Li H, Lu R, et al. Interferon antagonist proteins of influenza and vaccinia viruses are suppressors of RNA silencing. Proc Natl Acad Sci USA 2004; 101:1350-5.
31. Andersson M, Haasnoot P, Xu N, Berenjian S, Berkhout B, Akusjarvi G. Suppression of RNA interference by adenovirus virus-associated RNA. J Virol 2005; 79:9556-65.
32. Watanabe S, Watanabe T, Noda T, et al. Production of novel Ebola virus-like particles from cDNAs: an alternative to Ebola virus generation by reverse genetics. J Virol 2004; 78:999-1005.